CAR T cells: Building on the CD19 paradigm

A clinically applicable and scalable method to regenerate T-cells from iPSCs for off-the-shelf T-cell immunotherapy

(2021) Shoichi Iriguchi et al.   Nature Communications

Utility of Safety Switch to Abrogate CD19.CAR T Cell-Associated Neurotoxicity

(2021) Matthew C Foster et al.   BLOOD

Current State of the Art of Allogeneic CAR Approaches – Pile ‘Em High and Sell ’Em Cheap

(2021) Stefanos Theoharis   JOURNAL OF PHARMACEUTICAL SCIENCES

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

(2021) Nikhil C. Munshi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Engineering advanced logic and distributed computing in human CAR immune cells

(2021) Jang Hwan Cho et al.   Nature Communications

Targeting loss of heterozygosity for cancer-specific immunotherapy

(2021) Michael S. Hwang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CAR-T cell therapy: current limitations and potential strategies

(2021) Robert C. Sterner et al.   Blood Cancer Journal

A review of cancer immunotherapy toxicity

(2020) Lucy Boyce Kennedy et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Less is more: reducing the number of administered chimeric antigen receptor T cells in a mouse model using a mathematically guided approach

(2020) Anat Globerson Levin et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Enhancing Chimeric Antigen Receptor T cell Efficacy in Solid Tumors

(2020) Giovanni Fucá et al.   CLINICAL CANCER RESEARCH

Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy

(2020) Cassie K. Chou et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

‘Off-the-shelf’ allogeneic CAR T cells: development and challenges

(2020) S. Depil et al.   NATURE REVIEWS DRUG DISCOVERY

Immunotherapy Deriving from CAR-T Cell Treatment in Autoimmune Diseases

(2020) Yuehong Chen et al.   Journal of Immunology Research

CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial

(2020) Nirali N. Shah et al.   JOURNAL OF CLINICAL ONCOLOGY

Human chimeric antigen receptor macrophages for cancer immunotherapy

(2020) Michael Klichinsky et al.   NATURE BIOTECHNOLOGY

Tuning the Antigen Density Requirement for CAR T-cell Activity

(2020) Robbie G. Majzner et al.   Cancer Discovery

The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses

(2020) Alireza Labani-Motlagh et al.   Frontiers in Immunology

Effect of CRISPR/Cas9-Mediated PD-1-Disrupted Primary Human Third-Generation CAR-T Cells Targeting EGFRvIII on In Vitro Human Glioblastoma Cell Growth

(2020) Tsutomu Nakazawa et al.   Cells

PanErbB-targeted CAR T-cell immunotherapy of head and neck cancer

(2020) Daniel Larcombe-Young et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Replacing cART with CAR-T Cells: Using Immunotherapy to Cure HIV

(2020) Sarah E. Beck et al.   MOLECULAR THERAPY

Senolytic CAR T cells reverse senescence-associated pathologies

(2020) Corina Amor et al.   NATURE

A Senescence-Centric View of Aging: Implications for Longevity and Disease

(2020) M. Borghesan et al.   TRENDS IN CELL BIOLOGY

Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia

(2020) Meir Rozenbaum et al.   Frontiers in Immunology

Co-Expression of IL-7 Improves NKG2D-Based CAR T Cell Therapy on Prostate Cancer by Enhancing the Expansion and Inhibiting the Apoptosis and Exhaustion

(2020) Cong He et al.   Cancers

Overcoming key challenges in cancer immunotherapy with engineered T cells

(2020) Silvia Arcangeli et al.   CURRENT OPINION IN ONCOLOGY

CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?

(2020) Jessica Wagner et al.   MOLECULAR THERAPY

Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis

(2020) Andras Heczey et al.   NATURE MEDICINE

Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial

(2020) Nirav N. Shah et al.   NATURE MEDICINE

Treatment of Multiple Myeloma using Chimeric Antigen Receptor T Cells with Dual Specificity

(2020) Anat Globerson Levin et al.   Cancer Immunology Research

Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies

(2020) Elizabeth L. Siegler et al.   Frontiers in Immunology

Tumor-associated carbohydrates and immunomodulatory lectins as targets for cancer immunotherapy

(2020) Natalia Rodrigues Mantuano et al.   Journal for ImmunoTherapy of Cancer

Chimeric antigen receptor (CAR) natural killer (NK)‐cell therapy: leveraging the power of innate immunity

(2020) Hind Rafei et al.   BRITISH JOURNAL OF HAEMATOLOGY

Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade

(2020) Shivani Srivastava et al.   CANCER CELL

In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo

(2020) N. N. Parayath et al.   Nature Communications

Automated generation of gene-edited CAR T cells at clinical scale

(2020) Jamal Alzubi et al.   Molecular Therapy-Methods & Clinical Development

Engineering and Design of Chimeric Antigen Receptors

(2019) Sonia Guedan et al.   Molecular Therapy-Methods & Clinical Development

Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus

(2019) Rita Kansal et al.   Science Translational Medicine

CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape

(2019) Mohamad Hamieh et al.   NATURE

Phase 1 trial of anti-CD19 chimeric antigen receptor T (CAR-T) cells with tumor necrosis alfa receptor superfamily 19 (TNFRSF19) transmembrane domain.

(2019) Paolo Fabrizio Caimi et al.   JOURNAL OF CLINICAL ONCOLOGY

A safe and potent anti-CD19 CAR T cell therapy

(2019) Zhitao Ying et al.   NATURE MEDICINE

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

(2019) Noopur Raje et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice

(2019) Yushu Joy Xie et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma

(2019) Jie Xu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A Metabolism Toolbox for CAR T Therapy

(2019) Xuequn Xu et al.   Frontiers in Oncology

The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells

(2019) Katrin Mestermann et al.   Science Translational Medicine

Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function

(2019) Selena Vigano et al.   Frontiers in Immunology

Slamming the brakes on lupus with CAR T cells

(2019) Rachael A. Clark   Science Immunology

Targeting cardiac fibrosis with engineered T cells

(2019) Haig Aghajanian et al.   NATURE

Local Manufacture of CD19 CAR-T Cells Using an Automated Closed-System: Robust Manufacturing and High Clinical Efficacy with Low Toxicities

(2019) Olga Molostova et al.   BLOOD

CD19-Directed Fast CART Therapy for Relapsed/Refractory Acute Lymphoblastic Leukemia: From Bench to Bedside

(2019) Cheng Zhang et al.   BLOOD

Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors

(2019) Rachel Grosser et al.   CANCER CELL

CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors

(2019) Linchun Jin et al.   Nature Communications

CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity

(2019) Wenyan Fu et al.   Nature Communications

Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies

(2019) Xinjie Xu et al.   Frontiers in Immunology

CAR T Cells Beyond Cancer: Hope for Immunomodulatory Therapy of Infectious Diseases

(2019) Michelle Seif et al.   Frontiers in Immunology

Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia

(2019) Ivetta Danylesko et al.   Current Research in Translational Medicine

Chimeric antigen receptor–modified T cells: CD19 and the road beyond

(2018) Alexander I. Salter et al.   BLOOD

A guide to manufacturing CAR T cell therapies

(2018) Philipp Vormittag et al.   CURRENT OPINION IN BIOTECHNOLOGY

Driving CARs on the uneven road of antigen heterogeneity in solid tumors

(2018) Nan Chen et al.   CURRENT OPINION IN IMMUNOLOGY

Glycan-directed CAR-T cells

(2018) Catharina Steentoft et al.   GLYCOBIOLOGY

T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma

(2018) Jennifer N. Brudno et al.   JOURNAL OF CLINICAL ONCOLOGY

Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma

(2018) Katarzyna C. Pituch et al.   MOLECULAR THERAPY

Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells

(2018) Margherita Norelli et al.   NATURE MEDICINE

CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade

(2018) Theodoros Giavridis et al.   NATURE MEDICINE

A novel chimeric antigen receptor containing a JAK–STAT signaling domain mediates superior antitumor effects

(2018) Yuki Kagoya et al.   NATURE MEDICINE

Chimeric Antigen Receptor Therapy

(2018) Carl H. June et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

(2018) Jae H. Park et al.   NEW ENGLAND JOURNAL OF MEDICINE

FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell‐Induced Severe or Life‐Threatening Cytokine Release Syndrome

(2018) Robert Q. Le et al.   ONCOLOGIST

Clinical and Biologic Correlates of Neurotoxicity Associated with CAR T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia (B-ALL)

(2018) Bianca D. Santomasso et al.   Cancer Discovery

NKT cells - New Players in CAR Cell Immunotherapy?

(2018) Katharina Kriegsmann et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell

(2018) Marco Ruella et al.   NATURE MEDICINE

Targeting Adenosine Receptor Signaling in Cancer Immunotherapy

(2018) Kevin Sek et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency

(2018) Judith Feucht et al.   NATURE MEDICINE

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

(2018) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy

(2017) Paul A. Beavis et al.   JOURNAL OF CLINICAL INVESTIGATION

Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective

(2017) Isabelle Rivière et al.   MOLECULAR THERAPY

Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection

(2017) Justin Eyquem et al.   NATURE

Therapeutic T cell engineering

(2017) Michel Sadelain et al.   NATURE

CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy

(2017) Terry J Fry et al.   NATURE MEDICINE

Chimeric antigen receptor T-cell therapies for lymphoma

(2017) Jennifer N. Brudno et al.   Nature Reviews Clinical Oncology

Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

(2017) Sattva S. Neelapu et al.   Nature Reviews Clinical Oncology

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells

(2017) Juliane Gust et al.   Cancer Discovery

Genome-Editing Technologies in Adoptive T Cell Immunotherapy for Cancer

(2017) Nathan Singh et al.   Current Hematologic Malignancy Reports

Global Manufacturing of CAR T Cell Therapy

(2017) Bruce L. Levine et al.   Molecular Therapy-Methods & Clinical Development

T Cell Fate at the Single-Cell Level

(2016) Veit R. Buchholz et al.   Annual Review of Immunology

L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity

(2016) Roger Geiger et al.   CELL

Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition

(2016) Jiangtao Ren et al.   CLINICAL CANCER RESEARCH

Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells

(2016) David F. Stroncek et al.   CYTOTHERAPY

Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells

(2016) Partow Kebriaei et al.   JOURNAL OF CLINICAL INVESTIGATION

Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease

(2016) Jennifer N. Brudno et al.   JOURNAL OF CLINICAL ONCOLOGY

At The Bedside: Clinical review of chimeric antigen receptor (CAR) T cell therapy for B cell malignancies

(2016) Olalekan O. Oluwole et al.   JOURNAL OF LEUKOCYTE BIOLOGY

459. Evaluation of Miltenyi ExpAct and TransAct CD3/28 Beads for CAR-T Cell Manufacturing

(2016) Xiuyan Wang et al.   MOLECULAR THERAPY

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy

(2016) Christine E. Brown et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gated chimeric antigen receptor T-cells: the next logical step in reducing toxicity?

(2016) David Marc Davies et al.   Translational Cancer Research

Clinical manufacturing of CAR T cells: foundation of a promising therapy

(2016) Xiuyan Wang et al.   Molecular Therapy-Oncolytics

New Cell Sources for T Cell Engineering and Adoptive Immunotherapy

(2015) Maria Themeli et al.   Cell Stem Cell

Designing chimeric antigen receptors to effectively and safely target tumors

(2015) Michael C Jensen et al.   CURRENT OPINION IN IMMUNOLOGY

CAR therapy: the CD19 paradigm

(2015) Michel Sadelain   JOURNAL OF CLINICAL INVESTIGATION

Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor

(2015) James N. Kochenderfer et al.   JOURNAL OF CLINICAL ONCOLOGY

Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo

(2015) D Sommermeyer et al.   LEUKEMIA

80. Depletion of High-Content CD14+ Cells from Apheresis Products is Critical for the Successful Transduction and Expansion of CAR T Cells During Large-Scale cGMP Manufacturing

(2015) Xiuyan Wang et al.   MOLECULAR THERAPY

Genomic discovery of potent chromatin insulators for human gene therapy

(2015) Mingdong Liu et al.   NATURE BIOTECHNOLOGY

Therapeutic potential of CAR-T cell-derived exosomes: a cell-free modality for targeted cancer therapy

(2015) Xiang-Jun Tang et al.   Oncotarget

Suppression of Murine Colitis and its Associated Cancer by Carcinoembryonic Antigen-Specific Regulatory T Cells

(2014) Dan Blat et al.   MOLECULAR THERAPY

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity

(2014) P. S. Adusumilli et al.   Science Translational Medicine

Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study

(2013) C. R. Y. Cruz et al.   BLOOD

Design and development of therapies using chimeric antigen receptor-expressing T cells

(2013) Gianpietro Dotti et al.   IMMUNOLOGICAL REVIEWS

A new approach to gene therapy usingSleeping Beautyto genetically modify clinical-grade T cells to target CD19

(2013) Harjeet Singh et al.   IMMUNOLOGICAL REVIEWS

Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy

(2013) Maria Themeli et al.   NATURE BIOTECHNOLOGY

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

(2013) Stephan A. Grupp et al.   NEW ENGLAND JOURNAL OF MEDICINE

CD19 CAR-Targeted T Cells Induce Long-Term Remission and B Cell Aplasia in an Immunocompetent Mouse Model of B Cell Acute Lymphoblastic Leukemia

(2013) Marco L. Davila et al.   PLoS One

PD-1- and CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses

(2013) V. D. Fedorov et al.   Science Translational Medicine

CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia

(2013) R. J. Brentjens et al.   Science Translational Medicine

Phenotypic and Functional Attributes of Lentivirus-modified CD19-specific Human CD8+ Central Memory T Cells Manufactured at Clinical Scale

(2012) Xiuli Wang et al.   JOURNAL OF IMMUNOTHERAPY

IL-12 Release by Engineered T Cells Expressing Chimeric Antigen Receptors Can Effectively Muster an Antigen-Independent Macrophage Response on Tumor Cells That Have Shut Down Tumor Antigen Expression

(2011) M. Chmielewski et al.   CANCER RESEARCH

A human memory T cell subset with stem cell–like properties

(2011) Luca Gattinoni et al.   NATURE MEDICINE

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

(2011) M. Kalos et al.   Science Translational Medicine

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

(2010) J. N. Kochenderfer et al.   BLOOD

Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy

(2010) C. S. Hinrichs et al.   BLOOD

Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells

(2010) J. N. Kochenderfer et al.   BLOOD

The promise and potential pitfalls of chimeric antigen receptors

(2009) Michel Sadelain et al.   CURRENT OPINION IN IMMUNOLOGY

Amelioration of Colitis by Genetically Engineered Murine Regulatory T Cells Redirected by Antigen-Specific Chimeric Receptor

(2009) Eran Elinav et al.   GASTROENTEROLOGY

Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells

(2008) B. G. Till et al.   BLOOD

Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates

(2008) Carolina Berger et al.   JOURNAL OF CLINICAL INVESTIGATION